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Abstract
Background: Accurate and precise QT interval measurement is very important for both
regulatory and drug developmental decision making. These measurements are often made
using a manual or semi-automated technique, and the associated variability necessitates
sample sizes of around 50 to 70 subjects in thorough QT/QTc studies. The purpose of this
study was to compare the reproducibility and precision of a semi-automated (SA) method and
a high-precision (HPQT) technique for ECG extraction and QT interval measurement on two
thorough QT/QTc (TQT) studies conducted in compliance with ICH E14.
Methods: Data from 35 healthy subjects from two different crossover TQT studies on treat-
ment with placebo and moxifloxacin was analyzed. Both methods examined the RR and QT
intervals measured in lead II or the lead with the highest quality T-wave on a single beat basis
using the QT algorithm included in the COMPAS software package. ECGs were measured at
a protocol-specific timepoint.
Results: The effect of moxifloxacin on the QTc interval was highly reproducible in the two
studies, and assay sensitivity was met with both methods. Pairwise comparison of QTcF
values between methods demonstrated high agreement with no bias, small mean differences
(below 1.5 ms) and narrow limits of agreement. HPQT improved the precision of the QTc
measurement by 31% in Study I (standard deviation of DQTcF: SA 8.9 ms; HPQT 6.3 ms)
and by 15% in Study II (SD: SA 9.7 ms; HPQT 8.3 ms).
Conclusions: The HPQT QT measurement technique detected the effect induced by
moxifloxacin with the same accuracy as SA techniques, and with clearly improved precision.
More precise QTc measurement has important implications in terms of lowering the likelihood
of false positive results and/or reducing the sample size in TQT studies, as well as improving
the utility of QT assessment in early clinical development. (Cardiol J 2011; 18, 4: 401–410)
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Introduction
With the advent of the International Confe-
rence for Harmonization (ICH) E14 guidance to as-
sess the QT/QTc interval in so-called thorough QT
(TQT) studies [1], there is increasing emphasis on
accurate and precise measurement of the QT inter-
val. The QT interval is the single regulatory bio-
marker used to assess the risk of arrhythmia due to
drug-induced impaired cardiac repolarization lead-
ing to the rare and sometimes fatal drug-induced,
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polymorphic ventricular tachycardia, torsades de
pointes. To demonstrate that a drug does not pro-
long the QT interval to such an extent that there is
a safety concern, a TQT study should statistically
exclude an effect of the drug on the placebo-con-
trolled change-from-baseline QTc (DDQTc) exceed-
ing 10 ms. To demonstrate the sensitivity of the
study, i.e. its ability to detect a small QTc prolon-
gation, a positive control that mildly prolongs the
QTc interval, usually moxifloxacin, is included [2].
Currently, most central ECG laboratories use
a so-called semi-automated (SA) measurement
technique: the placement of the calipers for inter-
val measurement is decided by a computer algo-
rithm and the measurements are thereafter adjust-
ed by the reader. Typically, the intervals from three
consecutive beats in each of three ECG strips at
each protocol timepoint are measured. The process
is often overseen by a cardiologist, who also per-
forms the assessment of T wave morphology chang-
es. The use of the SA measurement technique re-
sults in a variability of the primary endpoint
(DDQTc) that often requires a sample size of the
TQT study exceeding 50 subjects. With eight to ten
(and sometimes more) timepoints post-dosing with
triplicate ECG recordings in each of four treatment
groups/arms, this can result in a total of 6,000 or
more ECG tracings.
To simplify and accelerate the analysis of such
a large number of ECGs, scientists have been focus-
ing on the development of more precise QT measure-
ment techniques than those usually provided in re-
gular commercial ECG equipment for clinical prac-
tices [3]. A more precise QT measurement technique
would have several important advantages. Firstly,
when the sample size of the TQT study is unchanged,
a higher precision of measurements improves the
power of the study, thereby minimizing false positive
results. Using larger amounts of ECG data permits
the implementation of newer beat-to-beat methodo-
logies [4]. Alternatively, fewer subjects are needed
to obtain the same statistical power in TQT studies,
which are designed to exclude a threshold effect
(10 ms). Finally, with a more precise technique, QT
assessment can be done with greater confidence in
early clinical studies which have been designed for
other purposes, and include far fewer subjects.
Certain features of drug-induced impaired car-
diac repolarization are more complex to measure and
evaluate, such as changes of T and U wave morpho-
logy. Gross changes are observed mainly with potent,
selective blockers of the delayed rectifier potassium
current, IKr [5], while less pronounced changes, such
as those observed with moxifloxacin, require more
sophisticated computer algorithms to be detected [6].
In consequence, the ICH E14 guidance requires an
assessment of any T wave morphology changes
caused by the investigational drug in a TQT study.
A SA method handles this through visual inspection
and scoring of such changes. Currently, it seems
advisable to incorporate this assessment in any new
technique intended for use in TQT studies or other
studies where QT assessment may be an important
secondary objective [7].
In this study, we compared a standard SA mea-
surement technique using three replicates from
pre-determined times within each ECG timepoint
to a high-precision measurement technique (HPQT,
iCardiac Technologies, Rochester, NY, USA), which
uses computer derived QT measurements while
maintaining human oversight of quality and of scor-
ing of T/U wave morphology changes. We wanted
to test the hypothesis that this approach would re-
sult in more precise QT measurement while main-
taining the ability to detect the QT prolongation
induced by a single dose of moxifloxacin. We com-
pared the two methods on data from two TQT stu-
dies conducted in compliance with the ICH E14
guidelines. ECGs from placebo and moxifloxacin
treatment arms were included in the analysis, and
the effect of moxifloxacin on the DDQTcF was ana-
lyzed using a time-matched approach.
Methods
Study datasets
Study I, conducted by Pfizer (Sandwich, UK)
was a double-blind, randomized, five-way crossover
TQT study in 35 healthy volunteers (30 males, five
females). Subjects were 18 to 55 years of age with
a mean body weight of 75.3 kg (53.6 to 96.6 kg) and
body mass index (BMI) between 18 and 30 kg/m2.
All subjects were screened for clinically relevant
abnormalities in their medical history, were physi-
cally examined, including blood pressure and pulse
rate, and were required to have normal baseline
ECG with QTc interval < 430 ms for males and
< 450 ms for females. The ECGs were recorded
using the Philips Holter recording system and the
EASI lead configuration (Philips Health Care, San
Francisco, CA, USA). The lead equivalent to Lead II
was used for interval measurements. ECGs were
extracted at the following timepoints on the day of
dosing: –1.5, –1, –0.5 hours pre-dose, and 1, 2, 3, 4,
6 and 8 hours post-dose. Subjects were in the semi-
recumbent position at rest for 10 min prior to ECG
timepoints. Moxifloxacin was administered as an
open-label, single 400 mg tablet.
403
Borje Darpo et al., Improving precision of QT assessment
www.cardiologyjournal.org
Study II was a double-blind, randomized, four-
-way crossover TQT study in 70 healthy volunteers.
From this study, ECGs from the placebo and moxi-
floxacin arms from 35 subjects (20 males, 15 fe-
males) were randomly selected from one of the
databases (E-HOL-12-0140-008) of the Telemetric
and Holter ECG Warehouse [8]. Twelve-lead ECGs
were obtained using the Mortara H12+ Holter
(Mortara Instrument, Milwaukee, WI, USA) and
Lead II was used for interval measurements. ECGs
were extracted at the following timepoints on the
day of dosing: –1, –0.5, –0.25 pre-dose, and 1, 2, 3,
4, 5, 6, 8, and 12 hours post-dose. Blinding of moxi-
floxacin was ensured through encapsulation and
a single dose of 400 mg was given.
At the core ECG laboratory (iCardiac Technolo-
gies), the same reader measured all ECGs from the
same subject with both measurement methods.
Readers were blinded to timepoints and treatments.
For both methods (SA and HPQT), ECG intervals
were measured using COMPAS, a software pack-
age developed at the University of Rochester Medi-
cal Center, Rochester, New York, USA [7].
Semi-automated QT method:
ECG selection and over-reading method
In Study I, three replicate 10-s ECGs were
extracted at 4 min, 2 min, and 10 s prior to each
nominal timepoint.
In Study II, three replicate 10-s ECGs extract-
ed at 4 min, 2 min and 0 s prior to each nominal time-
point. The QT/QTc intervals were measured on
three consecutive complexes from each ECG cho-
sen by analysts and the mean values from these
three complexes were computed. A replicate ECG
was non-evaluable when three sequential usable
beats could not be obtained from the replicate. For
each selected beat, the analyst adjusted the calipers
placed by COMPAS as required, following the stan-
dard approach for SA methodology. The mean of the
values from the three replicates was reported as the
QT/QTc values for each timepoint.
High-precision QT method
Ten ECG replicates were selected from among
non-overlapping 10-s ECGs available at each time-
point. The selection process was based on a ‘confi-
dence score’ designed as a combination of quality
metrics including beat stability, heart rate chang-
es, and signal-to-noise estimates. Heart rate stabi-
lity is a factor varying between 0% and 100%. It rep-
resents the percentage of beats within a replicate
ECG with a preceding RR value within a ‘stable’
range defined as ± 10% of the mean RR from the
previous 5 min period. In Study I, ten ECG repli-
cates were extracted within a 10 min window imme-
diately prior to each nominal timepoint. In Study II,
ten ECG replicates were selected within a 5 min
window centered on each nominal timepoint. The
COMPAS algorithm measured the QT interval in
all beats within a replicate. Beats were flagged for
analysts’ overread if an extremely small or large RR,
QT, QTcF, QTcF beat-to-beat change, or RR beat-
-to-beat value was observed. All ‘low confidence’
beats were reviewed manually by the ECG analyst,
using pass/fail criteria, i.e. an accepted interval was
included in the analysis, whereas a failed one was
not used.
In consequence, and in contrast to the SA
method, there was no mixing of manually adjusted
values with computer-measured values. T wave mor-
phology assessment with the HPQT method was per-
formed entirely manually (visually) on beats from
three replicates which were chosen based on high
quality criteria. The process was overseen by a car-
diologist, who also performed the final quality control.
The median values of the QT/QTc intervals
from all analyzed beats were calculated for each
replicate ECG. A replicate ECG was deemed non-
-evaluable when there were fewer than three usable
beats in the replicate. The mean of the evaluable
replicate median values was reported as the QT/QTc
values for that timepoint.
Statistical analysis
The ECG data was analyzed using a linear
mixed effects model with the following covariates:
time (categorical), treatment, time-by-treatment
interaction, and the baseline value of QTcF. The
response was the post-dose QTcF after baseline
adjustment, for which the average of the pre-dose
ECG timepoints was used. Subject was included as
a random effect. The estimates of DDQTcF values
and their two-sided 90% confidence intervals (CI)
were then calculated based on the fitted linear
mixed effects model. The standard deviation of the
DQTcF values for each nominal timepoint was also
provided and the possible reduction in the sample
size estimation was illustrated.
Pairwise comparison of the QTcF values at all
timepoints obtained from semi-automated and high-
precision methods was carried out via the method
proposed by Bland and Altman [9]. The mean of the
differences and the limits of agreement (defined as
± 1.96 standard deviations [SD] of the differences)
were calculated. The mean difference indicates any
potential bias of one method over another, and the
limits of agreement indicates the variability in the
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differences. A linear regression analysis of the
means and differences between the two methods
was performed and associated 95% CI of the fitted
slopes were given to show the potential linear
trends between the two variables.
To compare the time-matched QTcF measure-
ments, the time-matched mean difference in QTcF
between the moxifloxacin and placebo groups after
baseline adjustment (DDQTcF) was used as the end-
point, as per E14 guidance [1, 2]. Assay sensitivity
based on DDQTcF after dosing of moxifloxacin was
tested at 1, 2, 3 and 4 hours, and deemed to have
been met if the lower bound of the CI exceeded
5 ms at any of these timepoints, after adjustment for
multiplicity using two common approaches, Hoch-
berg’s procedure [10] and Bonferroni correction [11].
Outlier analyses were used to determine the
number and percentage of subjects that had QTcF
interval increases from baseline of > 30 ms to 60 ms
and > 60 ms. Each subject was considered having
an outlier value based on the most extreme value
across all of the timepoints.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Results
Changes in QTcF interval from baseline
Both SA and HPQT produced very similar
change-from-baseline QTcF (DQTcF) in all treatment
arms and at all timepoints in both studies (Fig. 1).
In Study I, the difference between methods of the
mean DQTcF ranged over timepoints from 0 to
1.6 ms in the placebo arm and between 0.1 to
1.7 ms for moxifloxacin. In Study II, the difference
between mean DQTcF for SA and HPQT ranged
from 0.1 to 3 ms (at 1 h) for placebo and between
0 and 1.8 ms for moxifloxacin.
Time-matched placebo-adjusted
changes in QTcF
Placebo-corrected DQTcF (DDQTcF) changes
were in strong agreement for both studies, and
mean differences between SA and HPQT methods
were less than 2.4 ms for Study I and less than 2.0 ms
for Study II at all timepoints (Table 1). In Study I, the
mean DDQTcF was above 10 ms between 1 and
4 hours after dosing with both methods. The lower
bound of the CI was above 5 ms at all timepoints
with HPQT and at all timepoints except 6 hours with
SA, where the largest difference of means between
methods was observed (2.4 ms). The largest mean
DDQTcF for Study II was seen at 3 hours with both
methods; DDQTcF was above 10 ms at 3, 4 and
5 hours with SA and at 2, 3, 4 and 5 hours with HPQT.
The lower bound of CI exceeded 5 ms at 2 to 6 and
12 hours post-dosing with both SA and HPQT.
When Hochberg’s procedure was used to adjust
for multiplicity for the 1 through 4 hours timepoints,
assay sensitivity was determined at all four timepoints
with both methods in Study I. Using Bonferroni, as-
say sensitivity was determined at all four timepoints
for HPQT and three timepoints for SA (1, 3, and 4 h
post-dose). In Study II, assay sensitivity was deter-
mined at three timepoints with HPQT (2, 3, and 4 h
post-dose) and two timepoints with SA (3 and 4 h post-
-dose) with both methods for adjustment. Overall,
when adjusted for multiplicity, assay sensitivity for the
study was achieved with both SA and HPQT.
Figure 1. DQTcF across timepoints following dosing with either placebo or 400 mg moxifloxacin; A, B. Mean (± 90%
two-sided confidence interval) changes in QTcF occurring in Study I (n = 35) and Study II (n = 35), respectively;
SA — semi-automated; HPQT — high-precision QT interval measurement.
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Pairwise comparison via the
Bland-Altman analyses
Bland-Altman plots over all pairwise differenc-
es of QTcF intervals measured with SA and with
HPQT demonstrated good agreement between
methods (Figs. 2, 3). The mean of the pairwise dif-
ferences was below 1.5 ms in Study I and below
0.8 ms in Study II, with limits of agreement below
12.7 ms and 11.3 ms, respectively (Table 2). In both
studies, the slopes of the regression lines charac-
terizing the relationship between the pairwise dif-
ference of QT measurements and their average
Table 1. DDQTcF [ms] across timepoints after 400 mg oral moxifloxacin.
Study Time Mean N SE 90% CI Mean N SE 90% CI
Lower Upper Lower Upper
I Moxifloxacin SA Moxifloxacin HPQT
1 11.8 34 1.7 8.9 14.6 11.4 34 0.9 9.8 13.0
2 10.0 34 2.1 6.4 13.6 11.4 34 0.8 10.0 12.7
3 12.5 34 1.7 9.5 15.4 10.9 34 1.2 8.9 12.9
4 10.8 34 1.9 7.6 13.9 10.7 34 1.4 8.4 13.1
6 6.0 29 2.3 2.1 9.9 8.4 29 1.8 5.5 11.4
8 9.7 32 2.4 5.7 13.8 8.4 32 1.9 5.2 11.6
II Moxifloxacin SA Moxifloxacin HPQT
1 5.3 35 2.4 1.3 9.3 7.3 35 2.5 3.2 11.5
2 8.9 35 1.9 5.6 12.2 10.1 35 1.4 7.7 12.4
3 15.3 35 2.0 11.9 18.8 14.3 35 1.5 11.8 16.7
4 13.2 35 2.2 9.5 16.9 12.2 35 1.8 9.2 15.3
5 11.2 34 1.9 8.0 14.3 10.6 34 1.4 8.2 13.1
6 9.4 34 2.5 5.1 13.7 8.7 34 1.9 5.5 11.8
8 6.7 34 2.1 3.2 10.2 7.7 34 1.7 4.8 10.5
12 9.1 33 1.9 6.0 12.3 9.3 33 1.2 7.3 11.3
SE — standard error; CI — confidence interval; SA — semi-automated; HPQT — high-precision QT interval measurement
Figure 2. Pairwise comparison of QTcF intervals generated by high-precision (HPQT) and semi-automated (SA)
measurements from Study I. Solid line represents mean difference for all timepoints between methods bounded by
1.96 standard deviation (dotted line) for 35 subjects given either placebo (A) or moxifloxacin (B).
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value were not significantly different from zero
(Table 2). This demonstrates that the agreement
of QT measurements between the HPQT and SA
methods is consistent across the overall range of
QT values.
Comparison of standard deviation
of the DQTcF
In Study I, the SD for DQTcF was lower for
HPQT than for SA at all timepoints on placebo, and
for all except one (8 h) on moxifloxacin. The mean
SD of DQTcF across treatments and timepoints was
reduced from 8.9 ms with SA to 6.3 ms with HPQT
(31% reduction), and the reduction was larger in the
placebo arm (41%) than in the moxifloxacin arm
(21%). In Study II, the level of reduction of SD
seemed smaller. The SD of DQTcF was lower at all
timepoints on both treatments with HPQT, with the
reduction ranging from 2% to 32%. The mean SD
for both treatments and all timepoints was reduced
from 9.7 ms to 8.3 ms, a reduction of 15% (Fig. 4).
Outlier analyses
For both studies, there were no subjects with
QTcF increases from baseline of > 60 ms after pla-
cebo or moxifloxacin. In Study I, no subjects on pla-
cebo, and one subject in the moxifloxacin arm, had
a DQTcF measured by HPQT between 30 and
60 ms. In Study II, one subject on placebo had
a DQTcF measured by SA between 30 and 60 ms.
On moxifloxacin, eight subjects had DQTcF values
between 30 ms and 60 ms as measured by SA, and
four subjects when using HPQT.
Discussion
This study compared a standard semi-automated
(SA) technique, which is commonly used by central
Figure 3. Pairwise comparison of QTcF intervals generated by high-precision (HPQT) and semi-automated (SA)
measurements from Study II. Solid line represents mean difference for all timepoints between methods bounded by
1.96 standard deviation (dotted line) for 35 subjects given either placebo (A) or moxifloxacin (B).
Table 2. Summary of Bland-Altman analyses.
Study Treatment Mean difference Limits of Slope (95% confidence P value
[ms] agreement [ms]  interval) [ms]  for slope
I Placebo –1.5 12.5 0.04 (–0.00, 0.09) 0.08
Moxifloxacin –1.4 12.7 0.04 (–0.00, 0.09) 0.08
II Placebo –0.8 11.1 0.00 (–0.04, 0.04) 0.94
Moxifloxacin –0.7 11.3 –0.02 (–0.06, 0.01) 0.17
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ECG laboratories, with a high-precision technique
(HPQT) for QT interval measurement in healthy
volunteers. Data from two thorough QT (TQT)
studies was analyzed using the same computer al-
gorithm for the QT interval measurements, which
were done by the same reader at the core lab.
Our results demonstrate that both methods de-
tected the QTc prolongation caused by a single-dose
of moxifloxacin with very similar level and timing of
the peak effect (Table 1); with both methods, the ‘as-
say sensitivity’ test requirements were met [1, 2]. The
bias between methods using Bland-Altman plots and
analyses was negligible. Importantly, the precision of
the QT measurement, as determined by the SD of the
DQTcF, was reduced by HPQT by, on average, 31%
and 15% in Studies I and II, respectively.
When comparing methods for extraction and
analysis of ECG data, the ICH Q&A document, is-
sued in 2008 [2], discusses several approaches
which we have employed in the present study:
— looking at the peak and time course of the mean
DDQTcF effect of the positive control;
— determining whether the study is sufficiently
sensitive to detect a 5 ms DDQTcF effect;
— performing a pairwise comparison using Bland-
-Altman plots.
Finally, we have also compared the precision
of the two methods, since an improvement has an
important impact on the power of the QT assess-
ment.
Peak and time course of DDQTcF of the
positive control. In studies in healthy volunteers,
it is important to ensure that emerging methods
result in similar levels of drug-induced QTc prolon-
gation when compared to available methods. It is
less critical that the absolute QTc values are iden-
tical. A single-dose of 400 mg moxifloxacin is the
most widely-used positive control in TQT studies
and causes an effect on the DDQTc of about 8 to
15 ms [12–14]. The peak effect in our studies was
12.5 ms and 11.4 ms for SA and HPQT, respective-
ly, in Study I, and 15.3 ms and 14.3 ms in Study II.
The full time course of DDQTcF was comparable
between methods, with a largest difference at any
timepoint of 2.4 ms in Study I and 2.0 ms in Study II.
The level and timing of the moxifloxacin QTc
peak effect in our studies was consistent with that
observed in other studies using manual, SA or fully
automated ECG measurement approaches [14–17].
Clearly, both traditional (e.g. fully manual and SA)
and more modern ECG techniques, paired with
strict handling and standard experimental condi-
tions at the clinical sites, seem to enable the de-
tection of a relatively small QTc effect in healthy
volunteer studies of a size that is often used in TQT
studies, i.e. 40 to 60 subjects [18–21].
Assay sensitivity. A TQT study’s ‘assay sen-
sitivity’ has been defined as the ability to statisti-
cally detect an effect level close to the threshold of
‘regulatory concern’ (5 ms), i.e. the lower 90% con-
fidence bound should exceed 5 ms [1]. On our
datasets from two TQT studies, both SA and HPQT
clearly met the assay sensitivity criterion at seve-
ral timepoints; when adjusted for multiplicity for
1 through 4 hours post-dosing, the assay sensitivity
test was met at three to four timepoints with HPQT
and at two to four timepoints with SA. This is also
the case in most TQT studies where the peak ef-
fect of moxifloxacin often reaches 10 ms or more,
and most methods for QT measurement are precise
enough to result in a confidence interval that ex-
ceeds 5 ms with commonly used sample sizes.
Figure 4. Comparison of standard deviations of DQTcF values [ms] after placebo and moxifloxacin. Values represent
mean standard deviation at each timepoint from 35 subjects in each study and treatment group; SA — semi-
-automated; HPQT — high-precision QT interval measurement.
408
Cardiology Journal 2011, Vol. 18, No. 4
www.cardiologyjournal.org
In instances where this criterion is not met, it can
be caused by either a lower-than-expected peak
effect of moxifloxacin or a low precision of the QT
measurements. An example of failed assay sensi-
tivity due to low precision of the QT measurement
was recently provided in the publication by Morgan-
roth et al. [18] from a TQT study with silodosin, an
alpha-blocker, conducted in 55 healthy male volun-
teers. The peak effect of moxifloxacin was in the
expected range (peak DDQTcI of 9.6 ms), but the
CI was very wide (12.6 ms), translating into a SD
of DDQTcI of approximately 18 ms. This meant that
the lower bound of the CI never exceeded 5 ms and
therefore, assay sensitivity as defined by ICH E14
[1, 2] was not met. However, it should be noted that
many factors in the conduct of a study can contri-
bute to the overall QT variability.
Pairwise comparison using Bland-Altman
plots. These plots allow pairwise comparison of
absolute QTc measurement. The strength of this
analysis is that it can disclose a bias between meth-
ods that correlates with the absolute QTc value, i.e.
whether differences between methods tend to grow
with increasing QTc intervals. Such a difference
between methods within a range of QTc intervals
that will be closely scrutinized for any degree of
prolongation would obviously be of concern, and
raise questions in regard to which method repre-
sents the most accurate QTc measurement [16, 17].
In our study, the regression line through all data
pairs showed either a non-significant, very shallow
slope or no slope at all, which is comforting.
The ‘limits of agreement’ (LoA) of the Bland-
-Altman plots describe the variability of the pairwise
differences between compared methods and is often
defined as ± 1.96 SD of these differences. There are
no well-defined boundaries for acceptability using
this approach. However, a LoA below ± 15 ms seems
to indicate good agreement [15–17, 22–24]. In our
two studies, the LoAs were well below this level,
indicating an excellent agreement between methods.
To some extent this is confirmed by the low mean
of the differences, which were less than 1.5 ms on
both placebo and moxifloxacin in both studies.
Precision of QT measurement. Using ECGs
extracted from the same timepoints from two TQT
studies, HPQT improved the precision of the QTc
measurement by up to 61% per timepoint in Study I
and by up to 32% in Study II. The level of improve-
ment seemed clearly larger in Study I, in which the
precision was improved by 41% in the placebo arm
and by 21% in the moxifloxacin arm; overall, the SD
of DQTcF was reduced from 8.9 ms to 6.3 ms, a 31%
improvement. The improvement in Study II was
17% on placebo and 13% on moxifloxacin and the
mean SD of DQTcF across timepoints was reduced
from 9.7 ms to 8.3 ms, a 15% improvement of the
precision. These differences between Studies I
and II illustrate that precision is not only about QTc
measuring technique. Many other factors can also
influence the end result.
The precision of QTc measurement can be es-
timated from published TQT studies by looking at
the width of the DQTc or DDQTc. Table 3 summa-
Table 3. Precision of DQTc in recently published TQT studies.
Study N Design QTc Mean DDQTc DDQTc CI Width of CI SD of DQTc Method
[ms]  [ms]  [ms]  [ms]
Morganroth 47 P QTcF 9.6 3.3 to 15.9 12.6 18.4 SA
et al. 2010 [18]
Moore et al. 2010 [19] 41 XO QTcF 14.1 9.7 to 18.5 8.8 12 Manual
De Kam et al. 2010 [21] 82 XO QTcI 20.8 UB 23.1 4.6 8.9 Manual
March and Cardi 51 P QTcI 9.4 UB 14.0 9.2 14 SA
2009 [28]
Poordad et al. 2009 [29] 60 XO QTcF 10 6.9 to 13.1 6.2 10.2 SA
Vandemeulebroecke 73 XO QTcF 10.3 7.8 to 12.7 4.9 8.9 Manual
et al. 2009 [30]
Dalen et al. 2010 [25] 35 XO QTcX 10 7.5 to 12.5 5.0 6.3 Eclysis
Tyl et al. 2009 [17] 62 XO QTcF 17.4 LB 13.5 7.8 13.1 Fully
automated
62 XO QTcF 19.9 LB 16.9 6.0 10.1 SA1
62 XO QTcF 17.5 LB 14.7 5.6 9.4 SA2
CI — 90% confidence interval; P — parallel; XO — crossover; QTcX — study-specific QTc correction; QTcI — subject-specific QTc correction;
UB — upper bound of 90% CI; LB — lower bound of 90% CI; SA — semi-automated
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rizes some key parameters of recently published
TQT studies in healthy volunteers, for which we
have estimated the precision of DQTcF using this
approach. Again, it should be emphasized that such
a head-to-head comparison between studies entails
many components that are not influenced by the
measuring technique, and results should therefore
be interpreted cautiously. Within this limitation, it
seems that the precision of the HPQT technique on
our studies (6.3 ms and 8.3 ms) is better than in the
published studies using manual or SA techniques,
in which the SD ranges from 8.9 ms to 18.4 ms. The
most precise estimate in Table 3 is seen with the
Eclysis technique in the publication by Dalen et al.
[25], which also resulted in very good precision of
DQTc (SD: 6.3 ms); this measurement technique
is also a computerized, highly precise approach,
which analyzes much more ECG data than conven-
tional SA or manual techniques, with some human
oversight [26]. Interestingly, in a recent study com-
paring SA to fully automated methods in 62 healthy
volunteers, the variability was higher with the fully
automated technique (SD for DQTcF on moxifloxacin:
13.1 ms) than with two tested SA techniques (SD:
10.1 and 9.4 ms) [16]. These results, combined with
those from our study, indicate that some degree of
human oversight and intervention, as employed in
HPQT methods, may be the optimal way to improve
the precision of QT measurement, while also provi-
ding an evaluation of T wave morphology changes.
Precision matters for two important reasons:
1. Using more precise techniques for QTc measu-
rement allows for substantially improved po-
wer of TQT studies, which enables reduction
of the sample size or the risk of false positive
results. As an example, improving the preci-
sion of DQTcF from 9.3 ms to 7.3 ms would
allow a reduction of the sample size from 58 to
37 subjects, with unaltered power (90%) and
assumptions.
2. More precise estimates of the QTc interval will
allow implementation of these techniques in
early clinical studies. Combined with concen-
tration effect modeling, precise estimates of
QTc effect may substantially improve the abi-
lity to detect QTc prolongation early in the
development process, and may eventually re-
place the TQT study [27].
Conclusions
A high-precision technique for the extraction
of ECGs and the measurement of QT intervals was
highly comparable to a conventional SA technique
in terms of the QTc effect induced by the positive
control, and resulted in a clear improvement of the
precision of the QTc estimate in two separate TQT
studies.
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